Our results indicate that high expression of BCL2L2 leads to resistance to Lenvatinib and that downregulation of this protein may increase HCC sensitivity to Lenvatinib in vivo and in vitro, which agrees with a previous study showing that Bcl-2 can effectively curb ovarian cancer cell apoptosis through resistance to cisplatin [33]. Here, BCL2L2 is linked to ovarian cancer.